24 results about "Type IV collagen" patented technology

The invention provides recombinant IV type collagen and application thereof, and relates to the technical field of protein engineering. In the invention, an amino acid residue repetitive unit with good biological activity and stability in the human-derived IV-type collagen is found, and the amino acid residue repetitive unit is used as a core for repeating and constructing the recombinant IV-type collagen, so that the novel human-derived recombinant IV-type collagen with biological activity is obtained. The human-derived recombinant IV-type collagen provided by the invention is a small-molecular-weight protein, is easy to absorb by a human body, is good in safety, can remarkably promote secretion of collagen, also has the effects of promoting cell adhesion and cell migration, and has a good application prospect in the aspects of basement membrane repair and remodeling. A new functional component is provided for products for repairing and tightening the skin, resisting aging, resisting wrinkles, preserving moisture and the like.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

This invention provides the application of type IV collagen and its encoding gene in the prognostic assessment and treatment of nasopharyngeal carcinoma (NPC). Research has shown that high expression of type IV collagen and its encoding gene COL4A1 is significantly associated with lower T-cell infiltration in patients with recurrent NPC; compared to NPC patients with low expression of type IV collagen, those with high expression have worse LRRFS and OS; and the expression level of the type IV collagen encoding gene COL4A1 is significantly associated with worse PFS in NPC patients. Therefore, type IV collagen and its encoding gene COL4A1 can serve as specific prognostic biomarkers for assessing the prognosis of NPC patients. Furthermore, inhibiting the expression of type IV collagen can effectively inhibit the growth of NPC; therefore, agents that inhibit type IV collagen expression can be used as drugs to inhibit immune escape in NPC and for the treatment of NPC.

Immunoassay methods for detecting HNE-generated fragments of the α3 or α4 chain of type IV collagen in a patient sample and their use for detecting and / or monitoring inflammatory bowel disease (IBD) or a particular level of severity of the disease in a patient are disclosed. Also disclosed are monoclonal antibodies and assay kits for use in the immunoassay methods.

The application relates to a preparation method and application of royal jelly acid double-wrapped bodies, and belongs to the technical field of cosmetics. The royal jelly acid double-wrapped body prepared by the application is obtained by co-wrapping royal jelly acid by phospholipid lipids and hydroxypropyl-beta-cyclodextrin, and the double-wrapping system of the hydroxypropyl-beta-cyclodextrin and the liposome improves the loading capacity of the royal jelly acid, has good stability, can significantly improve the solubility of the royal jelly acid, and is convenient for application in cosmetics; compared with pure royal jelly acid, the royal jelly acid double-wrapped body prepared by the application has more excellent skin permeability and more excellent effect of improving the content of type IV collagen of skin, and can provide mechanical support for skin and maintain the young state of skin.

Disclosed herein are medical products, including an implantable device coated with an extracellular matrix comprising Type IV collagen and laminin, wherein the implantable device comprises at least one member selected from the group consisting of sensors, meshes and cannulas, and the extracellular matrix contains no more than 0.024 mg / ml total concentration of glucose, amino acids and salts having a molecular weight of 2000 daltons or less. Corresponding systems and method also are disclosed.

The invention relates to the technical field of cosmetics, in particular to russula vinosa extract and a preparation method and application thereof.The preparation method comprises the steps that dried russula vinosa is smashed, production water is added, heating and stirring are conducted, filtering is conducted, filtrate is reserved, production water is supplemented into filter residues, heating and stirring are continued, filtering is conducted, filtrate is reserved, production water is supplemented into the filter residues again, and the russula vinosa extract is obtained; continuously heating, stirring and extracting, filtering, and retaining filtrate; combining the three filtrates, and carrying out solid-liquid separation to obtain a clear and transparent russula vinosa extracting solution; and concentrating and drying the russula vinosa extracting solution to obtain the russula vinosa extract. The method is simple in process and high in extraction efficiency, meanwhile, the content of type I collagen, type IV collagen and elastin can be remarkably increased on the cellular level by the russula vinosa extract with the concentration of 2 mg / mL, the density of collagenous fibers and elastic fibers can be remarkably increased on human skin explant tissue, and the russula vinosa extract has good anti-wrinkle and firming effects and is suitable for being used as a skin care product. A new raw material choice is provided for preparing the anti-wrinkle and firming cosmetics.

The application relates to the cosmetic technical field, in particular to a high-efficiency anti-aging composition and a skin care product containing the same. The high-efficiency anti-aging composition is prepared from the following raw materials in parts by mass: 12-15 parts of oil-based concentrated active ingredients, 25-35 parts of base collagen liquid, 15-18 parts of ikar, 12-16 parts of TWEEN 20, and 22-25 parts of isosorbide dimethyl ether. The oil-based concentrated active ingredients include safflower seed oil, acmella oleracea flower / leaf / stem extract, Astragalus membranaceus (Fisch.) Bunge root extract, ubiquinone and vitamin E. The base collagen liquid includes type XVII collagen, type VII collagen and type IV collagen. The composition can effectively reduce skin wrinkles, improve skin tightness and reduce skin sagging in a long term, and prevent skin aging, and realizes long-term anti-aging from epidermis to dermis.

This invention belongs to the field of renal pathology testing technology and discloses a method for detecting type IV collagen expression in renal biopsy tissue, comprising the following steps: dewaxing and hydrating paraffin sections of renal biopsy tissue to obtain processed tissue sections; adding the processed tissue sections to a repair solution, heating to boiling, and then cooling to room temperature to obtain repaired tissue sections; adding protease to the repaired tissue sections for enzymatic digestion to obtain enzymatically digested tissue sections; adding a primary antibody to the enzymatically digested tissue sections for preliminary incubation, followed by adding a fluorescein-labeled secondary antibody against the primary antibody for further incubation. This method for detecting type IV collagen expression in renal biopsy tissue is applicable to cases where renal biopsy tissue lacks glomeruli or has too few glomeruli to detect type IV collagen expression. It has high specificity and can provide a new detection method for Alport syndrome in cases where renal biopsy tissue lacks glomeruli.

The invention belongs to the technical field of oral care, and discloses application of beta-hydroxybutyric acid and an oral care product. The invention provides a novel application of beta-hydroxybutyric acid. The beta-hydroxybutyric acid is found to be capable of effectively promoting the expression of I-type collagen, III-type collagen, IV-type collagen and VII-type collagen; therefore, the oral mucosa healing can be effectively promoted, the oral mucosa barrier is repaired and strengthened, and the oral mucosa repair and gingival repair are promoted; and the oral care product with any one of the effects of promoting oral mucosa healing, repairing and strengthening oral mucosa barrier, promoting oral mucosa repair and repairing gingiva is formed.

The invention discloses a preparation method and application of recombinant humanized IV-type collagen, particularly discloses an optimized nucleotide sequence for coding M6 protein, and discovers that a carrier containing a plurality of optimized nucleotide sequences and a carrier containing CPB and KEN2 nucleotide sequences are co-transformed into cells through a large amount of screening, so that the recombinant humanized IV-type collagen is obtained. The expression quantity of the M6 protein can be obviously improved, and the obtained M6 has very good cell proliferation and migration activity.

An assay measuring protease mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment is described.

Described herein is an assay for measuring protease-mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment.

Provided are a method for screening a truncated bioactive peptide of type IV collagen by using a bioinformatics method, a truncated peptide obtained by means of the method, and an application thereof. Further provided is a method for obtaining the truncated peptide by means of fermentation using a yeast expression system.

The embodiment of the present application discloses a type IV collagen recombinant antigen and application. From N terminal to C terminal, the amino acid sequence fragments shown as SEQ ID NO. 1, the amino acid sequence fragments shown as SEQ ID NO. 2 and the amino acid sequence fragments shown as SEQ ID NO. 3 are sequentially spliced. The multi-subunit fragments α2 (7S), α3 (724-778) and α5 (NC1) are recombined in the present application, so that the recombinant IVC antigen with considerable expression amount and stability can be obtained, the antibody affinity after immunization can be increased, and the IVC antibody with higher titer can be obtained.

The present application belongs to the technical field of cosmetics, and particularly relates to a recombinant humanized collagen composition, a preparation method and application. The present application first reports a recombinant humanized collagen composition, which is based on the independently developed recombinant humanized collagen, and through compounding chitosan, ectoine and other components, the application scene of the recombinant type IV collagen is effectively expanded; and the composition itself can reduce the ability of melanocytes to synthesize melanin, has the ability to scavenge free radicals, and can also reduce the amount of preservatives in the composition, effectively maintain the stability of the recombinant type IV collagen. The recombinant humanized collagen composition can be used for daily skin care, and can also help the recovery after medical and aesthetic surgery, and therefore has good practical application value.

This invention discloses an antibody or its antigen-binding fragment that targets the α5 chain of type IV collagen, belonging to the field of antibody and related technologies, and can be applied to the diagnosis of Alport syndrome.

An object is to provide a drug that effectively treats a vascular disorder caused by excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell. Provided are [1] a therapeutic agent for a vascular disorder associated with excessive synthesis and secretion of a type IV collagen protein; [2] a therapeutic agent for a disease caused by excessive synthesis and secretion of a type IV collagen protein; [3] a pharmaceutical composition for treatment of a vascular disorder associated with excessive synthesis and secretion of a type IV collagen protein; [4] a pharmaceutical composition for treatment of a disease caused by excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell; and [5] an agent that inhibits excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell, each of [1] to [5] containing sirolimus as an active ingredient.

The invention discloses a composition with a basilar membrane repairing effect and preparation and application of the composition, and the composition is prepared from the following components in percentage by mass: 0.01%-0.2% of recombinant IV type collagen, 0.4%-4.0% of yeast fermentation product extract, 0.01%-0.2% of acetyl tetrapeptide-9, 0.01%-0.2% of acetyl tetrapeptide-11, 4%-10% of 1, 2-hexanediol, 0.01%-0.5% of ethylhexylglycerin and the balance of water. The composition has the advantages that the skin cell activity can be greatly improved, and cell migration is promoted; and the repair of the basement membrane is effectively protected and promoted through the ways of remarkably promoting the growth of the components of the basement membrane, enhancing the skin barrier, resisting inflammation, relieving and the like.

A method for biosynthesizing the human structural material type IV collagen is provided. Provided herein is a recombinant collagen comprising a sequence such as that shown in SEQ ID NO:1. The recombinant collagen has good cell adhesion activity. The method herein utilizes genetic engineering technology to produce recombinant collagen, overcoming the deficiencies of the prior art.

The invention discloses a microneedle / GelMA hydrogel composite hernia patch and a preparation method thereof, the patch comprises a microneedle array layer and GelMA hydrogel, and the GelMA hydrogel covers and adheres to the root of a microneedle head. The microneedle array layer is used for realizing tissue fixation and local drug delivery, and the GelMA hydrogel is subjected to enzymatic crosslinking by an HRP / H2O2 system to form a stable structure and has good flexibility and wet adhesion performance. By combining the biodegradability and tissue integration characteristics of the IV type collagen and the adjustable mechanical and biological adhesion characteristics of the GelMA hydrogel, a minimally invasive, stable and degradable hernia repair scheme is realized, and the hydrogel can be firmly attached to the tissue surface without suture, can be gradually degraded and absorbed after operation, reduces foreign body reaction and organ adhesion, and has a good application prospect. The infection and recurrence risks are obviously reduced, and excellent biocompatibility and clinical application prospects are achieved.

The application discloses a heat-resistant and stable recombinant humanized type VII collagen as well as a preparation method and application thereof, and belongs to the technical field of genetic engineering. The amino acid sequence of the recombinant humanized type VII collagen is formed by connecting four type VII collagen functional fragments in series, and the coding nucleotide is obtained by Pichia pastoris preference optimization design. The sequence is inserted into a pPIC9K plasmid to construct a recombinant vector, and the engineering bacteria are obtained by electric transformation of Pichia pastoris GS115. The target protein rhCOL7 is prepared through fermentation and purification. The rhCOL7 protein has excellent thermal stability, can resist 115 DEG C moist heat sterilization, has no obvious degradation after being placed at 60 DEG C for 60 days, can significantly promote cell proliferation, migration and adhesion, and can specifically interact with type IV collagen. The application realizes efficient preparation of the recombinant humanized type VII collagen, the activity of which is high and the stability of which is good, and the recombinant humanized type VII collagen can be widely applied to the preparation of wound repair drugs, biological repair materials and cosmetics.

This invention provides a complex protein composition, product, and application for improving skin condition. The complex protein composition includes type IV collagen, type VII collagen, type XVII collagen, laminin 332, and fibronectin. This complex protein composition helps to improve skin condition, delay the appearance of aging, reduce wrinkles, and improve sagging. Simultaneously, it plays a positive role in repairing and supporting the skin barrier and extracellular matrix structure, which is beneficial for maintaining the stability and orderly remodeling of the skin microenvironment.

The application discloses a microneedle / GelMA hydrogel composite hernia patch and a preparation method thereof, the patch comprising a microneedle array layer and a GelMA hydrogel, the GelMA hydrogel covering and adhering to the root of the microneedle needle. The microneedle array layer is used for realizing tissue fixation and local drug delivery, the GelMA hydrogel is enzymatically crosslinked by an HRP / H2O2 system to form a stable structure, and has good flexibility and wet adhesion performance. The application combines the biodegradability and tissue integration characteristics of type IV collagen and the adjustable mechanics and biological adhesion characteristics of the GelMA hydrogel, realizes a minimally invasive, stable and degradable hernia repair scheme, can be firmly attached to the tissue surface without suturing, can be gradually degraded and absorbed after the operation, reduces foreign body reaction and organ adhesion, significantly reduces the risk of infection and recurrence, and has excellent biocompatibility and clinical application prospect.